MTOR and neoplasm: Further, the Patient 1 tumor, its derivative cell lines and UW-CSCC2 all harbored copy number amplifications in genes of the PI3K/mTOR signaling pathway (Table S4), as well as mutations in AKT3 (Figure 3), supporting this as a key targetable pathway in metastatic cSCC.